PBS, 40% Glycerol, 0.05%BSA, 0.03% Proclin 300
12 months from date of receipt / reconstitution, -20 °C as supplied
| 应用 | 稀释度 |
|---|---|
| WB | 1:1000 |
| FCM | 1:200 |
DAF regulates the complement system on the cell surface. It recognizes C4b and C3b fragments that are created during activation of C4 (classical or lectin pathway) or C3 (alternative pathway). Interaction of DAF with cell-associated C4b of the classical and lectin pathways interferes with the conversion of C2 to C2b, thereby preventing formation of the C4b2a C3-convertase, and interaction of DAF with C3b of the alternative pathway interferes with the conversion of factor B to Bb by factor D, thereby preventing formation of the C3bBb C3 convertase of the alternative pathway. Thus, by limiting the amplification convertases of the complement cascade, DAF indirectly blocks the formation of the membrane attack complex.
WB result of DAF/CD55 Mouse mAb
Primary antibody: DAF/CD55 Mouse mAb at 1/1000 dilution
Lane 1: HeLa whole cell lysate 20 µg
Secondary antibody: Goat Anti-Mouse IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 41 kDa
Observed MW: 70 kDa
(This blot was developed with high sensitivity substrate)
Flow cytometric analysis of LNCaP (Human prostate carcinoma epithelial cell, left) / HeLa (Human cervix adenocarcinoma epithelial cell, right) cells labelling CD55 antibody at 1/200 dilution (1 μg) / (red) compared with a Mouse monoclonal IgG (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). Goat Anti - Mouse IgG Alexa Fluor® 488 was used as the secondary antibody.
Negative control: LNCaP
您现在的位置：
